Vaxcyte Stock Investor Sentiment

PCVX Stock  USD 74.37  1.35  1.85%   
Slightly above 66 percent of all Vaxcyte's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Vaxcyte suggests that a large number of traders are confidant. Vaxcyte's investing sentiment can be driven by a variety of factors including economic data, Vaxcyte's earnings reports, geopolitical events, and overall market trends.

Comfort Level 66

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Vaxcyte's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Vaxcyte.

Vaxcyte Historical Sentiment

Although Vaxcyte's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Vaxcyte, such as negative comments on social media and news outlets, may cause fear in the market and push Vaxcyte's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Vaxcyte.
  

Vaxcyte Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Vaxcyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Vaxcyte Historical Investor Sentiment

Investor biases related to Vaxcyte's public news can be used to forecast risks associated with an investment in Vaxcyte. The trend in average sentiment can be used to explain how an investor holding Vaxcyte can time the market purely based on public headlines and social activities around Vaxcyte. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vaxcyte's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vaxcyte and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Vaxcyte news discussions. The higher the estimate score, the more favorable the investor's outlook on Vaxcyte.

Vaxcyte Maximum Pain Price Across April 17th 2025 Option Contracts

Vaxcyte's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Vaxcyte close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Vaxcyte's options.
16 hours ago at fool.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
fool News
a day ago at news.google.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Google News at Macroaxis
2 days ago at www.macroaxis.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Macroaxis News
3 days ago at www.macroaxis.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Macroaxis News
few days ago at www.macroaxis.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Macroaxis News
few days ago at www.macroaxis.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Macroaxis News
few days ago at www.macroaxis.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Macroaxis News
six days ago at news.google.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 2621 shares by Eydelman Mikhail of Vaxcyte at 70.388 subject to Rule 16b-3
Macroaxis News
over a week ago at thelincolnianonline.com         
J.Safra Asset Management Corp Buys 736 Shares of Vaxcyte, Inc.
news
over a week ago at benzinga.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
benzinga news
over a week ago at thelincolnianonline.com         
Disposition of 112 shares by Eydelman Mikhail of Vaxcyte at 72.37 subject to Rule 16b-3
news
over a week ago at thelincolnianonline.com         
Insider Selling Vaxcyte, Inc. COO Sells 8,000 Shares of Stock
news
over a week ago at www.macroaxis.com         
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
Macroaxis News
over a week ago at finance.yahoo.com         
Vaxcyte, Inc. Among the Cash-Rich Mid Cap Stocks to Buy Now
Yahoo News
Far too much social signal, news, headlines, and media speculation about Vaxcyte that are available to investors today. That information is available publicly through Vaxcyte media outlets and privately through word of mouth or via Vaxcyte internal channels. However, regardless of the origin, that massive amount of Vaxcyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vaxcyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaxcyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaxcyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaxcyte alpha.

Vaxcyte Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Elvia Cowan of 7716 shares of Vaxcyte at 25.92 subject to Rule 16b-3
12/16/2024
2
Disposition of 280 shares by Guggenhime Andrew of Vaxcyte at 90.241 subject to Rule 16b-3
12/18/2024
3
Disposition of 8000 shares by Wassil Jim of Vaxcyte at 2.42 subject to Rule 16b-3
01/02/2025
4
Disposition of 125 shares by Eydelman Mikhail of Vaxcyte at 86.52 subject to Rule 16b-3
01/06/2025
5
Disposition of 683 shares by Guggenhime Andrew of Vaxcyte at 87.7 subject to Rule 16b-3
01/21/2025
6
Vaxcyte GAAP EPS of -3.80 beats by 0.27
02/25/2025
7
Vaxcyte Inc Q4 2024 Earnings Call Highlights Strong Financial Health and Promising ...
02/26/2025
8
Acquisition by Pickering Grant of 193431 shares of Vaxcyte at 74.22 subject to Rule 16b-3
02/27/2025
9
Vaxcyte Earns Buy Rating from Guggenheim
02/28/2025
10
Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
03/04/2025

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.